The POSITIVE Phase IV Study: Interim 52-Week Results on Patient Well-Being With Tildrakizumab - European Medical Journal

This site is intended for healthcare professionals

Continue

The POSITIVE Phase IV Study: Interim 52-Week Results on Patient Well-Being With Tildrakizumab

Dermatology

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.